These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38279939)

  • 21. Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans.
    Blanquicett CJ; Raavi T; Mirk A; Johnson TM; Jaglal M; Cartwright EJ
    J Am Geriatr Soc; 2021 Dec; 69(12):3602-3607. PubMed ID: 34499744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Su F; Beste LA; Green PK; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):686-693. PubMed ID: 28195877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs.
    Beste LA; Glorioso TJ; Ho PM; Au DH; Kirsh SR; Todd-Stenberg J; Chang MF; Dominitz JA; Barón AE; Ross D
    Am J Med; 2017 Apr; 130(4):432-438.e3. PubMed ID: 27998682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C Care Continuum in a Human Immunodeficiency Virus (HIV) Positive Cohort: Data From the HIV Atlanta Veterans Affairs Cohort Study.
    Adekunle RO; DeSilva K; Cartwright EJ
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa085. PubMed ID: 32280724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Falcão F; Lopes C; Viegas E; Perez R; Aldir I; Farinha H; Carvalho A; Mirco A; Marques S; Bana E Costa T; Miranda AC; Lebre L; Peixe P; Chagas C; Mansinho K; Correia JM
    Acta Med Port; 2019 Mar; 32(3):189-194. PubMed ID: 30946789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
    Kurokawa K; Ohki T; Kato J; Fukumura Y; Imai M; Shibata C; Arai J; Kondo M; Takagi K; Kojima K; Seki M; Mori M; Toda N; Tagawa K
    J Med Case Rep; 2020 May; 14(1):62. PubMed ID: 32456712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    Ottman AA; Townsend ML; Hashem MG; Britt RB
    Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
    JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
    Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
    World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
    Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.
    Dever JB; Ducom JH; Ma A; Nguyen J; Liu L; Herrin A; Groessl EJ; Ho SB
    Dig Dis Sci; 2017 Jun; 62(6):1472-1479. PubMed ID: 28378246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.
    Moon AM; Green PK; Rockey DC; Berry K; Ioannou GN
    Aliment Pharmacol Ther; 2020 Feb; 51(3):364-373. PubMed ID: 31773763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.
    Torres AD; Sparvoli JMH; Sparvoli AC; Gonçalves CV
    Arq Gastroenterol; 2019; 56(4):394-398. PubMed ID: 31800735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Su F; Green PK; Berry K; Ioannou GN
    Hepatology; 2017 Feb; 65(2):426-438. PubMed ID: 27775854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines.
    Hwang EW; Thomas IC; Cheung R; Backus LI
    J Clin Gastroenterol; 2013 Mar; 47(3):264-70. PubMed ID: 23269309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
    Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
    Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
    Liu CH; Chang YP; Lee JY; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Lee FJ; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
    J Med Virol; 2024 May; 96(5):e29675. PubMed ID: 38746997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.